Global Custom Market Research Reports Provider Company

phone

Blepharitis - Pipeline Review, H1 2018

  • Published Date: 27 Feb 2018
  • Number of Pages: 58
  • Category: Pharmaceuticals
  • Country: Global

Blepharitis - Pipeline Review, H1 2018

Summary


Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H1 2018, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelids oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Blepharitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 6 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Publisher Name : Global Markets Direct


Introduction
Global Markets Direct Report Coverage
Blepharitis - Overview
Blepharitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Blepharitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Blepharitis - Companies Involved in Therapeutics Development
Allergan Plc
Hovione FarmaCiencia SA
InSite Vision Inc
Kala Pharmaceuticals Inc
Marinomed Biotechnologie GmbH
Merck & Co Inc
NicOx SA
Novaliq GmbH
Quorum Innovations LLC
Blepharitis - Drug Profiles
(doxycycline + omega 3 fatty acid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGN-195263 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISV-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISV-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loteprednol etabonate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qi-402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Blepharitis and Conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetracycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Blepharitis - Dormant Projects
Blepharitis - Product Development Milestones
Featured News & Press Releases
Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis
Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite™ for the Treatment of Blepharitis in Adults
Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List Of Tables

List of Tables
Number of Products under Development for Blepharitis, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Blepharitis - Pipeline by Allergan Plc, H1 2018
Blepharitis - Pipeline by Hovione FarmaCiencia SA, H1 2018
Blepharitis - Pipeline by InSite Vision Inc, H1 2018
Blepharitis - Pipeline by Kala Pharmaceuticals Inc, H1 2018
Blepharitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2018
Blepharitis - Pipeline by Merck & Co Inc, H1 2018
Blepharitis - Pipeline by NicOx SA, H1 2018
Blepharitis - Pipeline by Novaliq GmbH, H1 2018
Blepharitis - Pipeline by Quorum Innovations LLC, H1 2018
Blepharitis - Dormant Projects, H1 2018
 



List Of Figures

List of Figures
Number of Products under Development for Blepharitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018



PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2018 Edition The motivation for pharma companies outsourcing their manufacturing is often to do with

View Report

2018 Banking Competitor Profile: Barclays Barclays is one of the largest banks in the UK, and is a leading provider of all the main banking products. Mortgages are a particular strength

View Report

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2018 in Pharmaceuticals GlobalDatas Partnerships, Licensing, Investments and M&A Deals and Trends for April 2018 in Pharmaceuticals , report is an essential

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports